ASPREE: Stopping aspirin does not appear to benefit or harm older adults

In a post hoc subgroup analysis of the ASPREE trial, those taking aspirin before the trial who were assigned placebo did not experience serious benefits or harms, researchers reported.
As Healio previously reported, in the main results of ASPREE, among adults aged at least 70 years with no history of CVD, aspirin did not reduce CVD risk and was associated with elevated risk for major hemorrhage compared with placebo.
For the present analysis, Mark R. Nelson, MBBS(Hons), MFM, PhD, head of Discipline of General Practice at Menzies Institute for Medical Research, University of Tasmania in

In a post hoc subgroup analysis of the ASPREE trial, those taking aspirin before the trial who were assigned placebo did not experience serious benefits or harms, researchers reported.
As Healio previously reported, in the main results of ASPREE, among adults aged at least 70 years with no history of CVD, aspirin did not reduce CVD risk and was associated with elevated risk for major hemorrhage compared with placebo.
For the present analysis, Mark R. Nelson, MBBS(Hons), MFM, PhD, head of Discipline of General Practice at Menzies Institute for Medical Research, University of Tasmania in